Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer

Download the slides, read the commentary, and view an on-demand webcast to gain expert insights on the implementation of targeted therapy and immunotherapy into (neo)adjuvant treatment regimens for patients with HER2-negative early breast cancer.

Share

Program Content

Activities

HER2 Negative EBC
Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2024

Expires: April 28, 2025

Activities

HER2-negative early breast cancer
Key Takeaways in the Management of HER2-Negative Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 08, 2024

Expires: May 07, 2025

HER2-Negative EBC With gBRCA PV
Key Takeaways in the Management of HER2-Negative Early Breast Cancer: Focus on Treating Patients With Pathogenic Variants in Germline BRCA
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 17, 2024

Expires: May 16, 2025

Activities

HER2neg EBC
Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 21, 2024

Expires: May 20, 2025

Provided by

ProCE Banner

Provided by ProCE, LLC, in partnership with Clinical Care Options

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner